Neptunus Bioengineering Holdings To Transfer Beidouxing Pharmaceutical
This article was originally published in PharmAsia News
Executive Summary
Neptunus Bioengineering Holdings plans to transfer its 100 percent stake in Changchun Beidouxing Pharmaceutical for RMB 40 million to Texas Petroleum. In addition, the company and its subsidiary Neptunus Interlong Bio-technique will sign a letter of intent on equity transfer and assets acquisition. To beef up Interlong's profit-making capability, Neptunus Bioengineering and its holding subsidiary Neptunus Medicine intend to sell their respective 75 percent and 5 percent stakes in Fuzhou Neptunus Futao Pharmaceuticals to Interlong. Interlong will on its part transfer its interferon and interleukin business to Neptunus Medicine. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.